文献速递胸部肿瘤放疗放疗物理与技术

光子、质子或碳离子用于I期非小细胞肺癌:ROCOCO多中心in silico研究结果

Photons, protons or carbon ions for stage I non-small cell lung cancer - Results of the multicentric ROCOCO in silico study.
PubMed 文献 · Radiother Oncol · 2018-03-12

ROCOCO多中心in silico研究对24例I期非小细胞肺癌患者比较光子(IMRT、VMAT、CyberKnife)、双散射质子(DSP)和调强碳离子(IMIT)计划的危及器官剂量与剂量递增可能性。处方为60 Gy(等效)分8次。粒子治疗平均危及器官剂量最低、CTV剂量更均匀,但鉴于VMAT和CyberKnife较IMRT可降低危及器官剂量,粒子的额外获益可能仅对选定患者有临床意义。

要点

  • 粒子治疗(DSP、IMIT)的危及器官平均剂量最低,CTV剂量更均匀。
  • IMIT对肺、心脏和纵隔结构剂量最低,DSP对脊髓剂量最低。
  • VMAT和CyberKnife较IMRT降低多数危及器官剂量;8例可剂量递增,纵隔为主要剂量限制器官。

核心结论

  • 总体上粒子治疗的危及器官剂量最低且CTV剂量更均匀,但粒子的额外获益可能仅对选定患者有临床意义,需个体化权衡。

研究设计与样本

  • ROCOCO多中心in silico研究,对24例I期非小细胞肺癌患者分别创建IMRT、VMAT、CyberKnife、DSP和IMIT计划,处方60 Gy(等效)分8次。

主要发现

  • 质子和碳离子的CTV平均剂量及2%CTV剂量低于IMRT(p < 0.01)。
  • IMIT对肺、心脏和纵隔结构的剂量最低(p < 0.01),DSP对脊髓剂量最低(p < 0.01)。
  • VMAT和CyberKnife较IMRT降低多数危及器官剂量;8例患者可行剂量递增,纵隔为主要剂量限制器官。

临床怎么用

  • 在I期NSCLC放疗选择光子或粒子技术时,应结合危及器官剂量与剂量递增可能性对每位患者个体化权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare dose to organs at risk (OARs) and dose-escalation possibility for 24 stage I non-small cell lung cancer (NSCLC) patients in a ROCOCO (Radiation Oncology Collaborative Comparison) trial. METHODS: For each patient, 3 photon plans [Intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and CyberKnife], a double scattered proton (DSP) and an intensity-modulated carbon-ion (IMIT) therapy plan were created. Dose prescription was 60 Gy (equivalent) in 8 fractions. RESULTS: The mean dose and dose to 2% of the clinical target volume (CTV) were lower for protons and ions compared with IMRT (p < 0.01). Doses to the lungs, heart, and mediastinal structures were lowest with IMIT (p < 0.01), doses to the spinal cord were lowest with DSP (p < 0.01). VMAT and CyberKnife allowed for reduced doses to most OARs compared with IMRT. Dose escalation was possible for 8 patients. Generally, the mediastinum was the primary dose-limiting organ. CONCLUSION: On average, the doses to the OARs were lowest using particles, with more homogenous CTV doses. Given the ability of VMAT and CyberKnife to limit doses to OARs compared with IMRT, the additional benefit of particles may only be clinically relevant in selected patients and thus should be carefully weighed for every individual patient.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wink KCJ, Roelofs E, Simone CB, et al. Photons, protons or carbon ions for stage I non-small cell lung cancer - Results of the multicentric ROCOCO in silico study. Radiother Oncol. 2018. PMID: 29545019. doi:10.1016/j.radonc.2018.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。